

December 14, 2020

BSE Limited

Corporate Relationship Department
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.
Scrip Code: 512529

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, Bandra-Kurla Complex,
Bandar (East),
Mumbai – 400 051.
Symbol: SEQUENT

Dear Sir/ Madam,

Sub: Change in Directorship

Pursuant to Regulation 30 (read with Part A of Schedule III) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors of the Company at its meeting held today, *inter-alia*, has approved appointment of Dr. Fabian Kausche (DIN: 08976500) as an Additional (Non-Executive Non-Independent) Director of the Company w.e.f. December 14, 2020, to hold office as such until the conclusion of ensuing Annual General Meeting of the Company.

Dr. Fabian Kausche has been nominated by CA Harbor Investments (Part of The Carlyle Group) as their nominee on the Board of the Company.

Brief profile and other information of Dr. Fabian Kausche pursuant to SEBI Circular bearing reference CIR/CFD/CMD/4/2015 dated September 9, 2015 is given in the enclosed 'Annexure A'.

We wish to take the above on record.

Thanking you,

Yours faithfully,

For **Sequent Scientific Limited**



Krunal Shah

Company Secretary & Compliance Officer



Encl.: A/a

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

“Annexure A”

Sr. No.	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	<p>Dr. Fabian Kausche (DIN: 08976500) appointed as an Additional (Non-Executive Non-Independent) Director of the Company.</p> <p>Dr. Fabian is a nominee of CA Harbor Investments (part of The Carlyle Group) on the Board of the Company.</p>
2.	Date of appointment/ Cessation	December 14, 2020
3.	Term of appointment	Appointed as an Additional Director (Non-Executive Non-Independent) of the Company w.e.f. December 14, 2020 to hold office until the conclusion of ensuing Annual General Meeting of the Company. His office is liable to retire by rotation.
4.	Brief profile (in case of appointment)	<p>Dr. Kausche is a Chairman of the Board of PetMedix, a start-up company in Cambridge, UK developing monoclonal antibodies for animals and Stonehaven Incubate, AG, an incubator bringing breakthrough human health technologies to animal health. He also owns and runs FK Consulting, LLC a company located in Atlanta specializing in supporting animal health companies in product innovation and organizational efficiency strategies and works as scientific advisor for Rejuvenate Bio a California-based startup that develops modern gene therapies for companion animals.</p> <p>Dr. Kausche has several decades of senior executive experience in the animal and human health industries in both biological and pharmaceutical research and development.</p> <p>He held subsequent positions as Global Head of Research & Development for three of the top eight global Animal Health companies: Novartis Animal Health, Merial, and Boehringer</p>

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>

		<p>Ingelheim Animal Health. Before leaving Boehringer Ingelheim Animal Health in December 2018, he led the post-merger integration of the largest R&D organization in the Animal Health industry with more than 1,200 scientist and support staff. In addition to his extensive Animal Health R&D experience, he gained additional expertise in the human health space as head of R&D for Novartis Consumer Health. Prior to that, he also successfully led a companion animal sales force for Novartis Animal Health.</p> <p>A native of Germany, Dr. Kausche received a veterinary degree from the Hannover Veterinary School. He subsequently completed a Master's of Science degree at Iowa State University. Following the completion of the M.S. degree, Dr. Kausche returned to Europe and took part in a research program that led him to receiving the German PhD (Dr.med.vet.) in a combination program between the Hannover Medical and Veterinary Schools. Having completed the Advanced Management Program in 2005, he is also an alumnus of Harvard Business School.</p>
5.	Disclosure of relationships between directors (in case of appointment of Director)	Dr. Fabian Kausche is not related to any other Director of the Company.

SeQuent Scientific Limited

Registered Office: 301, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Mumbai - 400604, India

Tel: +9122 4111777 | CIN: L99999MH1985PLC036685

<http://www.sequent.in>